Plus: Home-building slowed more than expected in August. And Eli Lilly says its investigational diabetes pill outperformed Novo Nordisk’s oral semaglutide in a clinical trial. Zoe Kuhlkin hosts.
Learn more about your ad choices. Visit megaphone.fm/adchoices